ISR - IsoRay, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
0.528
-0.021 (-3.910%)
As of 12:08PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.550
Open0.543
Bid0.533 x 100
Ask0.550 x 200
Day's Range0.528 - 0.550
52 Week Range0.480 - 0.700
Volume28,135
Avg. Volume89,810
Market Cap29.07M
Beta1.30
PE Ratio (TTM)-5.28
EPS (TTM)-0.1
Earnings DateNov 6, 2017 - Nov 10, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • ACCESSWIRE5 days ago

    Corporate News Blog - Antares Pharma Sells ZOMAJET(TM) Assets in a Potential $14.5 Million Deal

    Research Desk Line-up: IsoRay Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Antares ...

  • ACCESSWIRE6 days ago

    Earnings Review and Free Research Report: AngioDynamics Reported Lower than Expected Quarterly Results

    Research Desk Line-up: IsoRay Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 11, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on AngioDynamics, Inc. (NASDAQ: ANGO ...

  • Capital Cube7 days ago

    ETFs with exposure to IsoRay, Inc. : October 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to IsoRay, Inc. Here are 5 ETFs with the largest exposure to ISR-US. Comparing the performance and risk of IsoRay, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Should You Sell IsoRay Inc (ISR) For This Reason?
    Simply Wall St.12 days ago

    Should You Sell IsoRay Inc (ISR) For This Reason?

    IsoRay Inc (AMEX:ISR) announced a loss of -$6.17M in its most recent earnings update. Although some investors expected this, their belief in the path to profitability for ISR may beRead More...

  • IsoRay, Inc. :ISR-US: Earnings Analysis: Q4, 2017 By the Numbers : October 4, 2017
    Capital Cube13 days ago

    IsoRay, Inc. :ISR-US: Earnings Analysis: Q4, 2017 By the Numbers : October 4, 2017

    Categories: Yahoo FinanceGet free summary analysis IsoRay, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of IsoRay, Inc. – AngioDynamics, Inc. (ANGO-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 1.37 million, Net Earnings of USD -1.85 million. Gross margins ... Read more (Read more...)

  • IsoRay, Inc. :ISR-US: Earnings Analysis: 2017 By the Numbers : October 2, 2017
    Capital Cube15 days ago

    IsoRay, Inc. :ISR-US: Earnings Analysis: 2017 By the Numbers : October 2, 2017

    Categories: Yahoo FinanceGet free summary analysis IsoRay, Inc. reports financial results for the year ended June 30, 2017. We analyze the earnings along side the following peers of IsoRay, Inc. – AngioDynamics, Inc. (ANGO-US) that have also reported for this period. Highlights Gross margins widened from 2.71% to 17.60% compared to the same period last year, operating ... Read more (Read more...)

  • Associated Press19 days ago

    IsoRay reports 4Q loss

    On a per-share basis, the Richland, Washington-based company said it had a loss of 3 cents. The isotope-based medical products maker posted revenue of $1.4 million in the period. For the year, the company ...

  • IsoRay Announces Fourth Quarter Fiscal 2017 Revenue of $1.37 Million, 22% Fourth Quarter-over-Fourth Quarter Increase
    PR Newswire19 days ago

    IsoRay Announces Fourth Quarter Fiscal 2017 Revenue of $1.37 Million, 22% Fourth Quarter-over-Fourth Quarter Increase

    Gross Margin Expands to 36% on Continued Process Improvements and Expense Reduction RICHLAND, Wash. , Sept. 28, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator ...

  • IsoRay Announces Study Accepted for Publication in the International Journal of Radiation Oncology, Biology, Physics entitled "Re-irradiation using Permanent Interstitial Brachytherapy (PIB): A Potentially Durable Technique for Salvaging Recurrent Pelvic Malignancies"
    PR Newswire21 days ago

    IsoRay Announces Study Accepted for Publication in the International Journal of Radiation Oncology, Biology, Physics entitled "Re-irradiation using Permanent Interstitial Brachytherapy (PIB): A Potentially Durable Technique for Salvaging Recurrent Pelvic Malignancies"

    RICHLAND, Wash., Sept. 26, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the acceptance for publication of a study entitled "Re-irradiation using Permanent Interstitial Brachytherapy (PIB): A Potentially Durable Technique for Salvaging Recurrent Pelvic Malignancies" in the highly respected International Journal of Radiation Oncology, Biology, Physics (the "Red Journal").

  • IsoRay Announces "Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial" Poster Presentation at 2017 Annual American Society for Radiation Oncology (ASTRO) Conference
    PR Newswire22 days ago

    IsoRay Announces "Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial" Poster Presentation at 2017 Annual American Society for Radiation Oncology (ASTRO) Conference

    9 Year Study Demonstrates Durable Positive Outcomes and Statistically Identical Results of Cesium-131 RICHLAND, Wash. , Sept. 25, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology ...

  • Is IsoRay Inc (ISR) Undervalued?
    Simply Wall St.last month

    Is IsoRay Inc (ISR) Undervalued?

    IsoRay Inc (AMEX:ISR), a pharmaceuticals, biotechnology and life sciences company based in United States, received a lot of attention from a substantial price movement on the AMEX in the overRead More...

  • IsoRay Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017
    PR Newswire2 months ago

    IsoRay Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017

    RICHLAND, Wash., Aug. 31, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City. If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

  • IsoRay Announces Preliminary Fourth Quarter F2017 Revenue of $1.37 Million, 22% Year-over-Year Increase
    PR Newswire2 months ago

    IsoRay Announces Preliminary Fourth Quarter F2017 Revenue of $1.37 Million, 22% Year-over-Year Increase

    RICHLAND, Wash., Aug. 4, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced preliminary unaudited revenue and gross profit results for the fourth quarter and fiscal year ended June 30, 2017. Preliminary gross profit for the three months ended June 30, 2017 was $0.43 million compared to a loss of $0.05 million in the prior year period and $0.29 million in the third quarter of fiscal 2017. Gross profit margin was 31% in the current period compared to a negative gross margin in the fourth quarter of fiscal 2016 and 23% in the third quarter of fiscal 2017.

  • New Study Shows Brachytherapy And Cesium-131 Isotope Treatment Beneficial For Prostate Cancer Patients
    PR Newswire3 months ago

    New Study Shows Brachytherapy And Cesium-131 Isotope Treatment Beneficial For Prostate Cancer Patients

    The American Cancer Association published data shows nearly 200,000 cases of prostate cancer are diagnosed annually with one in seven men likely to be afflicted by the disease. Often, the options are either, invasive surgery, or extensive radiation treatment, both costly options. A treatment that has often been ignored is brachytherapy, which is not only more cost-effective but typically results in less treatment side-effects.

  • IsoRay Announces Appointment of Mark Austin as Controller, Principal Accounting and Financial Officer
    PR Newswire3 months ago

    IsoRay Announces Appointment of Mark Austin as Controller, Principal Accounting and Financial Officer

    RICHLAND, Wash., July 7, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the appointment of Mark Austin as Controller, Principal Accounting and Financial Officer. Mr. Austin's appointment is effective as of July 24, 2017. Mark Austin, CPA, has over 8 years of broad accounting experience in roles of increasing responsibility at KPMG.

  • IsoRay Receives FDA Response to 510(k) Application for GammaTile™
    PR Newswire3 months ago

    IsoRay Receives FDA Response to 510(k) Application for GammaTile™

    RICHLAND, Wash., July 6, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it has received a response from the FDA regarding the Company's pending 510(k) application for the GammaTile™ radiation therapy system. In its response, the FDA indicated the need for IsoRay, and its co-applicant GammaTile LLC, to submit additional data within the next 180 days as a condition of securing FDA clearance for the novel GammaTile™ device.

  • IsoRay Announces Study Published in The International Journal of Radiation Oncology, Biology, Physics entitled, "Clinical Outcomes of Large Brain Metastases Treated with Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy: Results of a Prospective Trial"
    PR Newswire4 months ago

    IsoRay Announces Study Published in The International Journal of Radiation Oncology, Biology, Physics entitled, "Clinical Outcomes of Large Brain Metastases Treated with Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy: Results of a Prospective Trial"

    Study Demonstrates 100% Freedom from Local Progression Rate & 0% Rate of Radionecrosis RICHLAND, Wash. , June 20, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator ...

  • Capital Cube4 months ago

    ETFs with exposure to IsoRay, Inc. : June 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to IsoRay, Inc. Here are 5 ETFs with the largest exposure to ISR-US. Comparing the performance and risk of IsoRay, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • IsoRay, Inc. :ISR-US: Earnings Analysis: Q3, 2017 By the Numbers : May 26, 2017
    Capital Cube5 months ago

    IsoRay, Inc. :ISR-US: Earnings Analysis: Q3, 2017 By the Numbers : May 26, 2017

    Categories: Yahoo FinanceGet free summary analysis IsoRay, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of IsoRay, Inc. – Accuray Incorporated, General Electric Company, Hologic, Inc., AngioDynamics, Inc., STRATA Skin Sciences, Inc., C. R. Bard, Inc. and Varian Medical Systems, Inc. (ARAY-US, GE-US, HOLX-US, ANGO-US, ... Read more (Read more...)

  • Associated Press5 months ago

    IsoRay reports 3Q loss

    The Richland, Washington-based company said it had a loss of 2 cents per share. The isotope-based medical products maker posted revenue of $1.3 million in the period. The company's shares closed at 57 ...

  • IsoRay Announces Third Quarter Fiscal 2017 Financial Results
    PR Newswire5 months ago

    IsoRay Announces Third Quarter Fiscal 2017 Financial Results

    RICHLAND, Wash. , May 10, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of ...

  • IsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics entitled "Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131"
    PR Newswire5 months ago

    IsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics entitled "Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131"

    RICHLAND, Wash., May 3, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the acceptance for publication of a study entitled "Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131" in the highly respected International Journal of Radiation Oncology, Biology, Physics (the "Red Journal").  The study was published on the Red Journal's website March 31, 2017 and will also be published in an upcoming issue of the Red Journal. The study was conducted by Sushil Beriwal, MD, Ryan P. Smith, MD, and Ronald M. Benoit, MD, from the departments of Radiation Oncology and Urology at the University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA.

  • Capital Cube6 months ago

    ETFs with exposure to IsoRay, Inc. : April 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to IsoRay, Inc. Here are 5 ETFs with the largest exposure to ISR-US. Comparing the performance and risk of IsoRay, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Accesswire6 months ago

    IsoRay, Inc. to Present at the Planet MicroCap Showcase 2017

    NEW YORK, NY / ACCESSWIRE / April 18, 2017 / IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, ...

  • Capital Cube6 months ago

    ETFs with exposure to IsoRay, Inc. : April 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to IsoRay, Inc. Here are 5 ETFs with the largest exposure to ISR-US. Comparing the performance and risk of IsoRay, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)